# A Study To Determine Any Effect Of Tafamidis On Electrocardiographic Intervals, Specifically The Rate Corrected QT Interval (QTc)

> **NCT01775761** · PHASE1 · COMPLETED · sponsor: **Pfizer** · enrollment: 42 (actual)

## Conditions studied

- TTR Cardiomyopathy

## Interventions

- **DRUG:** Period 1
- **DRUG:** Period 2
- **DRUG:** Period 3

## Key facts

- **NCT ID:** NCT01775761
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-01
- **Primary completion:** 2013-04
- **Final completion:** 2013-04
- **Target enrollment:** 42 (ACTUAL)
- **Last updated:** 2013-05-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01775761

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01775761, "A Study To Determine Any Effect Of Tafamidis On Electrocardiographic Intervals, Specifically The Rate Corrected QT Interval (QTc)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01775761. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*